GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Cyclically Adjusted Revenue per Share

MorphoSys AG (WBO:MOR) Cyclically Adjusted Revenue per Share : €5.22 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

MorphoSys AG's adjusted revenue per share for the three months ended in Dec. 2023 was €1.697. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €5.22 for the trailing ten years ended in Dec. 2023.

During the past 12 months, MorphoSys AG's average Cyclically Adjusted Revenue Growth Rate was 9.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 13.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of MorphoSys AG was 16.30% per year. The lowest was 4.10% per year. And the median was 10.20% per year.

As of today (2024-05-01), MorphoSys AG's current stock price is €66.15. MorphoSys AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €5.22. MorphoSys AG's Cyclically Adjusted PS Ratio of today is 12.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MorphoSys AG was 45.25. The lowest was 2.65. And the median was 23.25.


MorphoSys AG Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for MorphoSys AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Cyclically Adjusted Revenue per Share Chart

MorphoSys AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.06 3.58 3.86 4.71 5.22

MorphoSys AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.71 4.95 4.98 5.13 5.22

Competitive Comparison of MorphoSys AG's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, MorphoSys AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MorphoSys AG's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's Cyclically Adjusted PS Ratio falls into.



MorphoSys AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MorphoSys AG's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.697/123.6675*123.6675
=1.697

Current CPI (Dec. 2023) = 123.6675.

MorphoSys AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.604 99.543 0.750
201406 0.561 99.543 0.697
201409 0.624 99.823 0.773
201412 0.651 99.543 0.809
201503 2.676 99.717 3.319
201506 0.464 100.417 0.571
201509 0.430 100.417 0.530
201512 0.471 99.717 0.584
201603 0.462 100.017 0.571
201606 0.464 100.717 0.570
201609 0.477 101.017 0.584
201612 0.453 101.217 0.553
201703 0.412 101.417 0.502
201706 0.406 102.117 0.492
201709 0.519 102.717 0.625
201712 0.969 102.617 1.168
201803 0.096 102.917 0.115
201806 0.261 104.017 0.310
201809 1.738 104.718 2.053
201812 0.332 104.217 0.394
201903 0.429 104.217 0.509
201906 1.098 105.718 1.284
201909 0.395 106.018 0.461
201912 0.349 105.818 0.408
202003 7.847 105.718 9.179
202006 0.562 106.618 0.652
202009 0.672 105.818 0.785
202012 1.020 105.518 1.195
202103 1.441 107.518 1.657
202106 1.081 108.486 1.232
202109 1.205 109.435 1.362
202112 1.546 110.384 1.732
202203 1.214 113.968 1.317
202206 1.741 115.760 1.860
202209 2.803 118.818 2.917
202212 2.390 119.345 2.477
202303 1.824 122.402 1.843
202306 1.556 123.140 1.563
202309 1.867 124.195 1.859
202312 1.697 123.668 1.697

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


MorphoSys AG  (WBO:MOR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

MorphoSys AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=66.15/5.22
=12.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MorphoSys AG was 45.25. The lowest was 2.65. And the median was 23.25.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


MorphoSys AG Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


MorphoSys AG (WBO:MOR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Cyclically Adjusted Revenue per Share
Address
Semmelweisstrasse 7, Planegg, BY, DEU, 82152
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

MorphoSys AG (WBO:MOR) Headlines

From GuruFocus

MorphoSys AG Reports First Quarter 2022 Financial Results

By Business Wire Business Wire 05-04-2022

MorphoSys AG: Financial Calendar 2023

By ACCESSWIRE ACCESSWIRE 11-29-2022